NCT04090229 - A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 9, 2019

Primary Completion Date

October 28, 2021

Study Completion Date

December 3, 2021

Conditions

Atopic Dermatitis

Interventions

DRUG

ASLAN004

Subcutaneous injections of ASLAN004 100 mg/mL will be administered into the thigh or abdomen, except for the 2 inches (5 cm) around the navel.

DRUG

ASLAN004 Placebo

Subcutaneous injections of ASLAN004 Placebo will be administered into the thigh or abdomen, except for the 2 inches (5 cm) around the navel.

Trial Locations (11)

Premier Specialists Pty Ltd, Kogarah

Skin Health Institute, Inc., Carlton

Veracity Clinical Research Pty Ltd, Woolloongabba

Fremantle Dermatology, Fremantle

Paddington Testing Co, INC, Philadelphia

Direct Helpers Research Center, Miami

Dermatology Treatment and Research Cancer, Dallas

First OC Dermatology, Los Angeles

Center for Dermatology Clinical Research, INC, Fremont

National Skin Centre, Singapore

Changi General Hospital, Singapore